These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 8103770

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 3. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 4. Evidence that alpha 2-adrenergic pathways play a major role in growth hormone (GH) neuroregulation: alpha 2-adrenergic agonism counteracts the inhibitory effect of muscarinic cholinergic receptor blockade on the GH response to GH-releasing hormone, while alpha 2-adrenergic blockade diminishes the potentiating effect of increased cholinergic tone on such stimulation in normal men.
    Devesa J, Diaz MJ, Tresguerres JA, Arce V, Lima L.
    J Clin Endocrinol Metab; 1991 Aug; 73(2):251-6. PubMed ID: 1677361
    [Abstract] [Full Text] [Related]

  • 5. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [Abstract] [Full Text] [Related]

  • 6. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Minerva Endocrinol; 1999 May; 24(3-4):107-11. PubMed ID: 10953725
    [Abstract] [Full Text] [Related]

  • 7. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G, Grugni G, Morabito F.
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [Abstract] [Full Text] [Related]

  • 8. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M, Maccario M, Savio P, Valetto MR, Aimaretti G, Grottoli S, Oleandri SE, Baffoni C, Tassone F, Arvat E, Camanni F, Ghigo E.
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [Abstract] [Full Text] [Related]

  • 9. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
    Peñalva A, Burguera B, Casabiell X, Tresguerres JA, Dieguez C, Casanueva FF.
    Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
    [Abstract] [Full Text] [Related]

  • 10. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [Abstract] [Full Text] [Related]

  • 11. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 12. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L, Marziani E, Manzoni P, Arvat E, Valetto MR, Gianotti L, Ghigo E, Chiumello G.
    Dement Geriatr Cogn Disord; 1998 Nov; 9(2):78-81. PubMed ID: 9524798
    [Abstract] [Full Text] [Related]

  • 13. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A, Muruais C, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [Abstract] [Full Text] [Related]

  • 14. Growth hormone secretion in aging. Effect of pyridostigmine on growth hormone responsiveness to growth hormone-releasing hormone.
    Giusti M, Marini G, Sessarego P, Peluffo F, Valenti S, Caratti C, Giordano G.
    Recenti Prog Med; 1991 Dec; 82(12):665-8. PubMed ID: 1815302
    [Abstract] [Full Text] [Related]

  • 15. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
    Reichardt B, Schrader M, Mojto J, Mehltretter G, Müller OA, Schopohl J.
    J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
    [Abstract] [Full Text] [Related]

  • 16. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 17. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M, Bossoni S, Alí A, Doga M, Reimondo G, Milani G, Peretti P, Manelli F, Angeli A, Giustina A.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [Abstract] [Full Text] [Related]

  • 18. Glucocorticoids may inhibit growth hormone release by enhancing beta-adrenergic responsiveness in hypothalamic somatostatin neurons.
    Lima L, Arce V, Diaz MJ, Tresguerres JA, Devesa J.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):439-44. PubMed ID: 8094392
    [Abstract] [Full Text] [Related]

  • 19. Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy.
    Giustina A, Bossoni S, Bodini C, Girelli A, Balestrieri GP, Pizzocolo G, Wehrenberg WB.
    J Clin Endocrinol Metab; 1992 Jun; 74(6):1301-5. PubMed ID: 1592874
    [Abstract] [Full Text] [Related]

  • 20. Pyridostigmine potentiates growth hormone (GH)-releasing hormone-induced GH release in both men and women.
    Arvat E, Cappa M, Casanueva FF, Dieguez C, Ghigo E, Nicolosi M, Valcavi R, Zini M.
    J Clin Endocrinol Metab; 1993 Feb; 76(2):374-7. PubMed ID: 8432781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.